admin – Page 4151 – Get News Story

Patricia Louise Nelson, Attorney and Founder of Two Spruce Law P.C., Celebrates 30 Years of Legal Practice in Bend, Oregon

Over the course of her career, Nelson has been a champion for her clients and for other lawyers through numerous grassroots initiatives and participation in several local organizations

BEND, OREGON – FEBRUARY 12, 2025 – Patricia L. Nelson, founder of Two Spruce Law P.C., is celebrating thirty years of serving the Bend, Oregon, community with trusted legal services. Over the course of her career, Nelson has served as an advocate for her clients as well as for other lawyers via the participation in numerous local initiatives and organizations.

Nelson graduated magna cum laude from Williamette University College of Law in 1993 before embarking on her journey in law. She first served as a clerk for the Honorable Judge Edward Leavy of the Ninth Circuit Court of Appeals in Portland, Oregon. She was with Merrill O’Sullivan, LLP, for more than a decade before launching her own firm, Two Spruce Law P.C., in 2006.

Nelson has proudly been a part of boards over the past thirty years such as Oregon Women Lawyers, where she served as a board member and president; Growing Tree Children Center, where she served as board member and president; Cascade Women Lawyers, where she served as president; Deschutes County Bar Association, where she was president; and ConnectW, where she was a past president and board member. Nelson became an ordained minister in 2014 and has served as a board member of the Spiritual Awareness Community of the Cascades. In 2015, she became certified to teach Radical Collaboration.

In her practice, Nelson is passionate about working with her clients to achieve estate planning goals and offers a wealth of unique solutions and strategies including estate planning for pets. While planning for the end of life can be a difficult subject to broach, Nelson and her staff do so with kindness and compassion.

“Estate planning is critical for my clients and their loved ones,” said Nelson. “Some clients want to put a will, trust, or something else in place before their end of life, and other clients are trying to sort things out after a love one’s passing. We provide legal services to provide for every circumstance.”

Nelson and her team, which includes attorney Blake A. Robinson, paralegal Katya Sierra, paralegal Lucy Wesson, legal assistant Ian Ferguson, legal assistant Kimberly Washburn and bookkeeper Kerry Duncan, work together to ensure a seamless experience for their clients. By practicing personal law that honors the integrity of the client, Two Spruce Law P.C. continues its tradition of excellence with Nelson’s three decades of legal practice at its core. Learn more now and contact Nelson today by visiting twosprucelaw.com.

ABOUT TWO SPRUCE LAW P.C.

Two Spruce Law P.C. is a Bend, Oregon, based firm specializing in probate law and estate planning. With a focus on providing one-on-one, specialized client care, the team at Two Spruce Law P.C. practices law while honoring the client’s needs at every turn.

Media Contact
Company Name: Two Spruce Law P.C.
Contact Person: Patricia Louise Nelson
Email: Send Email
Phone: (541) 389-4646
Address:204 SE Miller Ave
City: Bend
State: OR 97702
Country: United States
Website: https://www.twosprucelaw.com

Protecting Future Welders: Clean Air Company Enhances Safety at Burlington County Institute of Technology with Advanced Fume Ventilation

Photo Courtesy: Clean Air Company

Clean Air Company, a leading air filtration and ventilation system provider in the Tri-State Area, installed a state-of-the-art welding fume ventilation system at the Burlington County Institute of Technology (BCIT). The system was created as part of Clean Air Company’s ongoing commitment to providing safe and healthy learning environments in educational institutions. The comprehensive ventilation system utilizes coral fume extraction arms in 30 welding booths to capture welding fumes and remove harmful particles from the air.

Removing Harmful Airborne Particles

Welding fumes contain tiny solid particles (.01 – 1 micrometer in diameter) created when metal vapors produced during welding cool and condense. The particles typically clump together to form larger aggregates (1 – 4 micrometers in diameter, depending on the type of welding method and metals used). The airborne particles can cause serious health issues when inhaled, including lung and respiratory problems. To ensure the safety of BCIT students and staff, Clean Air Company’s team of experts worked closely with the school to customize a ventilation system appropriate for their needs that effectively removes these harmful particles from the air.

The system includes highly efficient filters with minimum efficiency reporting values (MERV) of 15, which can capture up to 98% of particles during initial filtration. In addition, a secondary high-efficiency particulate air (HEPA) filter further purifies the air by removing up to 99.9% of the remaining particles before returning the air back into the classroom.

Reducing Operating Costs

Clean Air Company customized the ventilation system for BCIT to meet the school’s specific needs, demonstrating its expertise and commitment to customer satisfaction. Through collaborative efforts, Clean Air Company and BCIT achieved an optimized design that maximizes effectiveness while minimizing energy consumption.

One key feature of BCIT’s new ventilation system is its self-cleaning mechanism, which ensures that the system can continuously remove welding fumes from the air without any system downtime. The system monitors the filters for restricted airflow and automatically cleans them using compressed air until their lifespan is exhausted. This process guarantees clean air and reduces the school’s maintenance and operational costs, making it a cost-effective long-term solution.

Unlike traditional systems that exhaust tempered air outside, Clean Air Company’s system purifies and recirculates existing air, eliminating the need for constant exhaust and providing significant energy savings. This reduces energy costs and improves overall air quality in the school by continuously filtering out harmful particles.

Clean Air Company: A Trusted Partner

Clean Air Company has a proven track record of delivering effective industrial ventilation systems for various industries, including educational institutions. With over four decades of experience, they deeply understand the unique ventilation requirements of different environments. Their commitment to excellence makes them a trusted partner for schools seeking to improve indoor air quality.

In addition to installation, Clean Air Company offers comprehensive maintenance services to ensure the system continues to operate at peak efficiency. Regular maintenance checks and filter replacements guarantee that BCIT students and staff can continue learning and working in a healthy environment.

Clean Air Company’s installation at BCIT showcases its dedication to creating clean and healthy learning environments through innovative solutions. For more information about Clean Air Company’s products and services, please visit https://www.cleanairco.com/.

Media Contact
Company Name: Clean Air Company
Contact Person: Greg Slavin
Email: Send Email
Phone: (800) 738-0911
Country: United States
Website: https://www.cleanairco.com/

Joe Siecinski, Founder of brainSHARE Business Mentors, Author of “Brainshare: How Business Owners Make More Time and Have More Money,” Named One of 2025’s Elite Inspirational Leaders by CXO Time

“The greatest recognition comes from seeing a business owner rediscover their passion, a team achieve something they thought was impossible, or a community thrive because a business succeeded,” said Joe Siecinski.

Joe Siecinski, co-founder of brainSHARE Business Mentors, has been named an Inspirational Leader of 2025 for his transformative influence in entrepreneurship. Through programs like The Success Circle, Business Growth Accelerator, and Idea to Enterprise, he helps business owners crack the code to scalable success. His mission is to turn complexity into clarity, ensuring businesses thrive without sacrificing work-life balance.

Silicon Valley, CA – February 12, 2025 – In a landscape where business success is often measured by financial gain alone, true leadership is defined by vision, impact, and the ability to elevate others. Joe Siecinski, founder of brainSHARE Business Mentors, has been named an Elite Inspirational Leader of 2025 by CXO Time, a distinction that celebrates his relentless commitment to helping entrepreneurs build thriving businesses—without sacrificing their personal lives.

This recognition from CXO Time underscores Joe Siecinski’s transformative influence in the business world, where he has revolutionized the way entrepreneurs approach growth, strategy, and sustainability. With a career spanning decades of coaching and mentoring, Joe Siecinski has empowered thousands of business owners, equipping them with the tools, frameworks, and confidence to break through barriers and unlock unprecedented success.

Cracking the Code to Business Success

At the heart of his philosophy Joe Siecinski says, “Business isn’t just about profit—it’s about purpose, mastery, and balance.” Through brainSHARE Business Mentors, Joe Siecinsiki has pioneered a proven system that helps entrepreneurs crack the code to sustainable growth. This system, once available only through high-cost one-on-one mentoring, is now accessible to businesses of all sizes through brainSHARE.us, Joe Siecinski’s proprietary digital learning platform.

Programs like the Business Growth Accelerator help business owners who have hit a plateau implement scalable strategies that drive momentum. Meanwhile, the Idea to Enterprise program provides aspiring entrepreneurs with a structured roadmap to turn their vision into a reality, ensuring they have the right foundation in place before launching. And for those seeking ongoing mentorship, brainShare’s Success Circle offers a dynamic peer network and expert guidance to navigate challenges and sustain long-term business success.

From Insight to Impact: A Legacy of Leadership

Joe Siecinski’s inclusion on the 2025 list of Inspirational Leaders by CXO Time is a testament to his ability to ignite transformation. Joe Siecinski’s work has helped business owners not only increase profitability and efficiency but also redefine their relationship with work—ensuring that their businesses serve their lives, not the other way around.

“This honor isn’t about me,” said Joe Siecinski. “It’s about the thousands of entrepreneurs who have dared to think bigger, work smarter, and reclaim their time. My mission has always been to turn complexity into clarity, giving business owners the tools they need to thrive – without the overwhelm.”

An Invitation to the Next Generation of Business Leaders

As Joe Siecinski continues his mission through brainSHARE’s mentorship programs, digital courses, and live strategy sessions, he remains dedicated to shaping the next generation of entrepreneurs, innovators, and change-makers. His work serves as a beacon for those who refuse to settle, proving that with the right strategy, mindset, and support, any business can be both successful and fulfilling.

To learn more about Joe Siecinski and brainSHARE Business Mentors, visit brainshare.us

Media Contact
Company Name: BrainSHARE Business Mentors
Contact Person: Dave Kocharhook, Marketing VP
Email: Send Email
Phone: 4083348627
City: Silicon Valley
State: California
Country: United States
Website: https://www.brainshare.us/pages/home

Houston: The Premier Destination for Blepharoplasty with Dr. Raghu Athré

Houston, TX – Houston is emerging as the premier destination for blepharoplasty, drawing patients from across the country who seek the expertise of Dr. Raghu Athré at Athré Facial Plastics. As a double-board-certified facial plastic surgeon, Dr. Athré is at the forefront of advanced eyelid surgery, offering patients transformative results with a natural and refreshed appearance.

What sets Houston apart as a must-visit destination for blepharoplasty? The city’s reputation for excellence in facial plastic surgery is driven by Dr. Raghu Athré, a leading expert in the field. Renowned for his precision, innovation, and patient-centric approach, Dr. Athré has helped establish Houston as a premier hub for natural-looking, transformative results. His advanced techniques and commitment to excellence ensure that patients receive world-class care, making Houston the go-to city for those seeking top-tier blepharoplasty with an expert touch.

Dr. Athré is certified in both facial plastic surgery and otolaryngology (head and neck surgery), equipping him with unparalleled expertise in facial anatomy. His approach prioritizes subtle, harmonious enhancements that maintain each patient’s unique features while avoiding an “overdone” appearance. Specializing in both the subciliary and transconjunctival approaches to lower blepharoplasty, he customizes every procedure to meet the specific needs of his patients.

“Houston is home — it’s where I grew up and where my journey began. I wanted to bring advanced techniques to my community and offer a practice that focuses on relationships, not just procedures,” said Dr. Athré.

The combination of world-class surgical expertise, state-of-the-art technology, and a patient-first approach makes Houston the ultimate destination for those considering blepharoplasty. Whether addressing under-eye bags, drooping lids, or fine lines, Dr. Athré’s meticulous techniques and personalized care continue to attract patients seeking unparalleled results.

For more information or to schedule a consultation with Dr. Raghu Athré, visit https://www.athrefacialplastics.com/facial-surgery/blepharoplasty/ or call 281-214-9324.

About Dr. Raghu Athré

Dr. Raghu Athré is a double-board-certified facial plastic surgeon specializing in advanced cosmetic and reconstructive procedures. With years of experience, he has become one of the most trusted names in facial aesthetics, offering cutting-edge techniques and personalized care at his Houston-based practice.

Media Contact
Company Name: Fifth & Cor
Contact Person: Ana Cantos
Email: Send Email
Country: United States
Website: https://www.fifthandcor.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Houston: The Premier Destination for Blepharoplasty with Dr. Raghu Athré

South Florida Marketing & Innovation Firm Celebrates Third Year Anniversary

BOCA RATON, FL – Three years ago, Fifth & Cor was a bold vision fueled by ambition and creativity — a female-owned company built to transform industries through innovation and strategic thinking. Today, the marketing and innovation agency celebrates its third anniversary, reflecting on a journey marked by resilience, collaboration, and remarkable achievements.

From the very start, Fifth & Cor chose financial independence by remaining entirely self-funded and debt-free. This strategy demonstrated trust in its team, its vision, and its ability to innovate under pressure while creating meaningful economic impact for employees, clients, and partners.

Over the past three years, Fifth & Cor has pursued excellence with relentless determination. The company has hosted over 250 events nationwide, reaching audiences from intimate gatherings to major industry stages, and contributed over 500 hours of thought leadership through presentations, podcasts, and webinars. Energizing 25 cities with innovative campaigns and storytelling, they’ve reached audiences with powerful insights and strategies while inspiring industry change.

Collaboration drives Fifth & Cor’s success. With 50 strategic partnerships, the company has launched innovative campaigns, disrupted norms, and redefined community engagement. These efforts have supported 310+ businesses across industries, from aesthetics and real estate to fashion and hospitality.

Success stems from strategy and resilience — adapting to global challenges, market shifts, and tech advancements. Committed to excellence and innovation, Fifth & Cor continues to grow. Looking ahead, the agency is focused on bold campaigns, strategic partnerships, and industry-shaping opportunities for even greater impact.

“Entrepreneurship is a journey of uncertainty, challenges, and unexpected turns — but it’s also a path of innovation, creativity, and growth,” said Robin Dimond, CEO & Founder. “Three years ago, I took a leap of faith in a vision I believed in. The journey has tested me, but every challenge has shaped our success. I’m deeply grateful to our clients, partners, and incredible team — because every step, whether a blessing or a lesson, has led us here for a reason.”

For more information on Fifth & Cor and any inquiries, please visit https://www.fifthandcor.com/. For daily marketing updates and tips, follow us on LinkedIn, Instagram, Facebook and Twitter.

Media Contact
Company Name: Fifth & Cor
Contact Person: Ana Cantos
Email: Send Email
Country: United States
Website: https://www.fifthandcor.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: South Florida Marketing & Innovation Firm Celebrates Third Year Anniversary

Brain Cancer Market Expected to rise, 2034 | Y-mAbs Therapeutics Inc., Shimadzu Corporation, Bristol-Myers Squibb, Bayer AG, AstraZeneca plc, Johnson & Johnson Inc., Merck & Co., Pfizer Inc., F. Hoffm

“Brain Cancer market growth”

The Brain Cancer market growth is driven by factors like increase in the prevalence of Brain Cancer, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Brain Cancer market report also offers comprehensive insights into the Brain Cancer market size, share, Brain Cancer epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Brain Cancer market size growth forward.

Some of the key highlights from the Brain Cancer Market Insights Report:

Several key pharmaceutical companies, including Y-mAbs Therapeutics Inc., Shimadzu Corporation, Bristol-Myers Squibb, Bayer AG, AstraZeneca plc, Johnson & Johnson Inc., Merck & Co., Pfizer Inc., F. Hoffmann-La Roche Ltd, Dr. Reddy’s Laboratories Ltd, and others, are developing novel products to improve the Brain Cancer treatment outlook.
In January 2025, the FDA granted breakthrough device designation to CergenX’s AI-driven tool, Wave, for neonatal brain scans. This designation will allow the Irish startup to receive prioritized review and enhanced communication with FDA experts during the premarket review process.
In December 2024, Kazia Therapeutics’ stock dropped 26% to $2.28 after the FDA suggested it might consider standard approval but not accelerated approval for the company’s brain cancer drug, paxalisib. Over the year, the stock has declined by approximately 48%. Paxalisib, developed for the treatment of glioblastoma, demonstrated significant overall survival benefits in a July trial, which had previously led to a surge in the company’s stock.
The largest Brain Cancer market size in the 7MM was occupied by the US in 2023.
Among EU4 and the UK, Italy will capture the maximum revenue share, followed by Germany in 2034.
The US contributed to the largest incident-patient share, acquiring more than 38% of the 7MM in 2023.
Among the gender-specific cases, males are affected more than females, accounting for nearly 60% and 40% of cases respectively, in the US, in 2023.
Among the grade-specific cases, the cases of high-grade (III and IV) brain tumors are more incident than Low-Grade, accounting for nearly 70% of cases in the US.
In April 2024, the United States Food and Drug Administration (US FDA) granted accelerated approval to Day One Biopharmaceuticals’ OJEMDA (tovorafenib) as a treatment for patients 6 months of age and older with certain relapsed or refractory pediatric low-grade glioma.
In April 2024, TME Pharma announced that the US FDA granted Fast Track Designation for NOX-A12 (olaptesed pegol), TME Pharma’s CXCL12 inhibitor, in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer, glioblastoma.
In February 2024, Servier announced that the US FDA accepted the filing and granted priority review for the New Drug Application (NDA) for vorasidenib, and assigned a Prescription Drug User Fee Act (PDUFA) action date of August 20, 2024. If approved, vorasidenib would become a first-in-class targeted therapy for patients with IDH-mutant gliomas.
As per DelveInsight analysis, the Brain Cancer market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Brain Cancer Market Landscape

Brain Cancer Overview

A brain tumor, also referred to as an intracranial tumor, falls under central nervous system (CNS) tumors, which encompass a range of diseases characterized by the abnormal formation of mass lesions in the brain, spinal cord, or their protective coverings.

Brain tumors are broadly classified into two categories: primary and metastatic. Primary brain tumors are further categorized as “low grade” or “high grade.” Low-grade tumors typically grow slowly but may progress into high-grade tumors over time, whereas high-grade tumors are more aggressive and tend to grow rapidly.

In adults, secondary brain tumors, also known as brain metastases, are significantly more prevalent than primary brain tumors.

Do you know the treatment paradigms for different countries? Download our Brain Cancer Market Sample Report

Brain Cancer Epidemiology Insights

In 2023, the United States recorded the highest number of incident cases of primary brain tumors among the 7MM, with approximately 23,000 cases. This number is anticipated to rise over the forecast period.

Brain Cancer Epidemiology Segmentation

DelveInsight’s Brain Cancer market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Brain Cancer historical patient pools and forecasted Brain Cancer patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Brain Cancer Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

Brain Cancer Prevalence
Age-Specific Brain Cancer Prevalence
Gender-Specific Brain Cancer Prevalence
Diagnosed and Treatable Cases of Brain Cancer

Visit for more @ Brain Cancer Epidemiological Insights

Brain Cancer Market Outlook

Brain cancer treatment typically involves a combination of therapies, including surgery, chemotherapy, radiation, and stereotactic radiosurgery, often followed by adjuvant treatments. While treatment remains largely palliative, immunotherapy has emerged as a promising approach, leveraging the body’s immune system to combat tumor growth. This includes checkpoint inhibitors and cancer vaccines targeting tumor antigens, with ongoing research exploring gene and oncolytic virus therapies.

The market is highly competitive, with numerous companies actively developing new therapeutic options. The FDA’s approval of OJEMDA positions it alongside Novartis’ TAFINLAR-MEKINIST combination, which is currently approved for pediatric low-grade glioma (pLGG) with BRAF V600 mutations. Leading pharmaceutical companies such as Genentech, Daiichi Sankyo, Bristol Myers Squibb, Bayer, Roche, AstraZeneca, and Pfizer are advancing their brain cancer treatments in mid-to-late-stage clinical trials. Once approved, these therapies are expected to significantly impact the market landscape.

Brain Cancer Marketed Drugs

AVASTIN (bevacizumab): Genentech
TEMODAR/TEMODAL: Merck

Brain Cancer Emerging Drugs

Vorasidenib: Servier
Paxalisib: Kazia Therapeutics

Brain Cancer Key Companies

Y-mAbs Therapeutics Inc.
Shimadzu Corporation
Bristol-Myers Squibb
Bayer AG
AstraZeneca plc
Johnson & Johnson Inc.
Merck & Co.
Pfizer Inc.
F. Hoffmann-La Roche Ltd
Dr. Reddy’s Laboratories Ltd, and others

For more information, visit Brain Cancer Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Brain Cancer Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Brain Cancer, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Brain Cancer epidemiology in the 7MM
Brain Cancer marketed and emerging therapies
Brain Cancer companies
Brain Cancer market drivers and barriers

Table of Contents:

1 Brain Cancer Market Key Comprehensive Insights

2 Brain Cancer Market Report Introduction

3 Competitive Intelligence Analysis for Brain Cancer

4 Brain Cancer Market Analysis Overview at a Glance

5 Executive Summary of Brain Cancer

6 Brain Cancer Epidemiology and Market Methodology

7 Brain Cancer Epidemiology and Patient Population

8 Brain Cancer Patient Journey

9 Brain Cancer Treatment Algorithm, Brain Cancer Current Treatment, and Medical Practices

10 Key Endpoints in Brain Cancer Clinical Trials

11 Brain Cancer Marketed Therapies

12 Brain Cancer Emerging Therapies

13 Brain Cancer: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Brain Cancer

16 Brain Cancer Market Key Opinion Leaders Reviews

18 Brain Cancer Market Drivers

19 Brain Cancer Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Brain Cancer Epidemiology 2034

DelveInsight’s “Brain Cancer – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Brain Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Brain Cancer Pipeline 2024

“Brain Cancer Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Brain Cancer market. A detailed picture of the Brain Cancer pipeline landscape is provided, which includes the disease overview and Brain Cancer treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Brain Cancer Market Expected to rise, 2034 | Y-mAbs Therapeutics Inc., Shimadzu Corporation, Bristol-Myers Squibb, Bayer AG, AstraZeneca plc, Johnson & Johnson Inc., Merck & Co., Pfizer Inc., F. Hoffm

Biliary Tract Cancer Market Expected to rise, 2034 | Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme,

“Biliary Tract Cancer Market 2034”

The Biliary Tract Cancer market growth is driven by factors like increase in the prevalence of Biliary Tract Cancer, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Biliary Tract Cancer market report also offers comprehensive insights into the Biliary Tract Cancer market size, share, Biliary Tract Cancer epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Biliary Tract Cancer market size growth forward.

Some of the key highlights from the Biliary Tract Cancer Market Insights Report:

Several key pharmaceutical companies, including Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, BeiGene, and others, are developing novel products to improve the Biliary Tract Cancer treatment outlook.
In November 2024, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Ziihera® (zanidatamab-hrii) 50mg/mL injection for intravenous use. This approval is for the treatment of adults with previously treated, unresectable, or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), identified through an FDA-approved test. Ziihera’s accelerated approval was based on a 52% objective response rate (ORR) and a median duration of response (DOR) of 14.9 months, as assessed by an independent central review. Continued approval will depend on confirming clinical benefit in a follow-up trial. The Phase 3 HERIZON-BTC-302 trial is ongoing, evaluating zanidatamab in combination with standard-of-care therapy compared to standard-of-care therapy alone for the first-line treatment of HER2-positive BTC.
In August 2024, Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company, completed patient enrollment in its COMPANION-002 trial, a randomized Phase 2/3 study with 150 patients. The trial evaluates CTX-009 for individuals with biliary tract cancer (BTC).
In June 2024, Bold Therapeutics, a leader in metallotherapeutics, announced positive Phase 2 safety and efficacy results for its lead asset, BOLD-100, in the treatment of advanced metastatic biliary tract cancer (BTC) and gastric cancer (GC) at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.
In 2023, the United States held the largest share of the Biliary Tract Cancer market in the 7MM, with nearly 48% of the market, compared to the EU4, the UK, and Japan. Among the EU4 and the UK, Italy had the largest market share for Biliary Tract Cancer, while Spain had the smallest.
In December 2024, Jazz Pharmaceuticals announced that the U.S. FDA had granted accelerated approval for Ziihera® (zanidatamab-hrii) 50mg/mL for intravenous administration. The drug is approved for the treatment of adults with previously treated, unresectable, or metastatic HER2-positive biliary tract cancer (BTC), as identified through an FDA-approved test.
Biliary tract cancers, which are epithelial malignancies of the biliary tree, include gallbladder cancer (GBC) and cholangiocarcinoma (CCA). CCA is further categorized into intrahepatic, perihilar (Klatskin’s tumor), and distal types. The symptoms of Biliary Tract Cancer vary based on tumor location. Extrahepatic tumors commonly cause painless jaundice due to biliary obstruction, while intrahepatic tumors typically present with pain. Patients often report pruritus, abdominal pain, fatigue, jaundice, and fever.
Diagnosis of Biliary Tract Cancer generally involves abdominal clinical examination, imaging scans such as ultrasound, MRI, or CT, and biopsy. In 2023, Japan recorded the highest number of new Biliary Tract Cancer cases in the 7MM.
In the United States, Biliary Tract Cancer predominantly affects individuals aged 70–79, representing about 30% of all age-specific cases. Among the EU4 and the UK, TP53 mutations were most common in Biliary Tract Cancer cases, followed by KRAS mutations in 2023.
For early-stage Biliary Tract Cancer, treatment typically includes surgery followed by adjuvant chemotherapy. In cases of locally advanced disease, loco-regional therapies such as trans-arterial chemoembolization (TACE) and external beam radiation therapy (EBRT) may be considered. For advanced and metastatic cases, a combination of gemcitabine and cisplatin has shown survival benefits.
Chemotherapy regimens dominate the current treatment landscape, but emerging therapies like CX-4945 and CTX-009 are expected to positively impact the treatment landscape between 2024 and 2034. Drugs like PEMAZYRE (pemigatinib) and LYTGOBI (futibatinib), both FGFR2 inhibitors, have been approved by the FDA. Another key target for Biliary Tract Cancer treatment is the PD-1 immune checkpoint molecule. In October 2023, the FDA expanded the use of KEYTRUDA (pembrolizumab) in combination with gemcitabine and cisplatin for treating locally advanced unresectable or metastatic Biliary Tract Cancer.
Researchers are also exploring other mutations in Biliary Tract Cancer tumors to develop more treatment options. TAFINLAR (dabrafenib) and MEKINIST (trametinib) have been approved for BRAFV600E solid tumors, while VITRAKVI (larotrectinib) and ROZLYTREK (entrectinib) are used for NTRK fusion-positive solid tumors.
Real-world data analysis reveals evolving treatment patterns and survival outcomes, showing variation in therapy use across treatment lines. Despite advancements, challenges such as low survival rates, high mortality, and factors like advanced age and disease stage complicate treatment decisions and patient outcomes.
As per DelveInsight analysis, the Biliary Tract Cancer market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Biliary Tract Cancer Market Landscape

Biliary Tract Cancer Overview

The biliary tract consists of the gallbladder and the intrahepatic and extrahepatic biliary trees. Bile flows through these ducts to the second part of the duodenum at the major duodenal papilla. The lining of the biliary tract is composed of cells known as cholangiocytes. Biliary tract carcinoma originates from the malignant transformation of the bile duct epithelium, which is made up of these cholangiocytes. It is classified based on its anatomical location into: 1) Intrahepatic cholangiocarcinoma, and 2) Extrahepatic cholangiocarcinoma, which includes perihilar tumors (also called Klatskin tumors) that arise from the bile duct epithelium at the junction of the right and left hepatic ducts and the cystic duct, forming the common bile duct, and distal cholangiocarcinoma, which can extend to the gallbladder, ampulla of Vater, and pancreatic biliary ducts.

Chronic inflammatory conditions can cause changes in the biliary tract epithelium, leading to cancer. One of the most well-established conditions linked to biliary tract cancer is primary sclerosing cholangitis (PSC), which is commonly associated with chronic inflammatory bowel diseases, particularly ulcerative colitis.

The clinical presentation of biliary tract cancer depends on the tumor’s location. Most tumors start at the hepatic duct bifurcation, while others occur in the distal common bile duct or within the liver. Patients with extrahepatic tumors typically present with painless jaundice due to biliary obstruction, whereas those with intrahepatic tumors generally experience pain.

Do you know the treatment paradigms for different countries? Download our Biliary Tract Cancer Market Sample Report

Biliary Tract Cancer Epidemiology Insights

In 2023, Italy had the highest number of Biliary Tract Cancer cases among the EU4 countries and the UK, with Germany following behind, while Spain had the fewest cases.
Regarding stage-specific cases, Stage IV had the highest incidence in Japan, and this number is expected to rise by 2034.

Biliary Tract Cancer Epidemiology Segmentation

DelveInsight’s Biliary Tract Cancer market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Biliary Tract Cancer historical patient pools and forecasted Biliary Tract Cancer patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Biliary Tract Cancer Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

Biliary Tract Cancer Prevalence
Age-Specific Biliary Tract Cancer Prevalence
Gender-Specific Biliary Tract Cancer Prevalence
Diagnosed and Treatable Cases of Biliary Tract Cancer

Visit for more @ Biliary Tract Cancer Epidemiological Insights

Biliary Tract Cancer Market Insights

Companies involved in the development of therapies for Biliary Tract Cancer include TransThera Sciences, AstraZeneca/Compugen, Jazz Pharmaceuticals/Zymeworks, and others. The launch of emerging therapies and additional treatments is expected to significantly boost the Biliary Tract Cancer market size during the forecast period from 2024 to 2034.

In 2023, the total market size for Biliary Tract Cancer was approximately USD 1 billion, with projections indicating growth by 2034 throughout the study period (2020–2034) in the 7MM.

The United States had the largest Biliary Tract Cancer market size in 2023, followed by Japan. During the forecast period, pipeline candidates like CX-4945 and CTX-009 are anticipated to contribute to the market’s expansion.

By 2034, chemotherapy regimens are expected to generate the largest Biliary Tract Cancer market size in the United States, reaching approximately USD 360 million.

Biliary Tract Cancer Marketed Drugs

PEMAZYRE (pemigatinib): Incyte
IMFINZI (durvalumab): AstraZeneca

Biliary Tract Cancer Emerging Drugs

CTX-009: Compass Therapeutics
Zanidatamab: Jazz Pharmaceuticals/Zymeworks

Biliary Tract Cancer Key Companies

Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, BeiGene, and others

For more information, visit Biliary Tract Cancer Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Biliary Tract Cancer Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Biliary Tract Cancer, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Biliary Tract Cancer epidemiology in the 7MM
Biliary Tract Cancer marketed and emerging therapies
Biliary Tract Cancer companies
Biliary Tract Cancer market drivers and barriers

Table of Contents:

1 Biliary Tract Cancer Market Key Comprehensive Insights

2 Biliary Tract Cancer Market Report Introduction

3 Competitive Intelligence Analysis for Biliary Tract Cancer

4 Biliary Tract Cancer Market Analysis Overview at a Glance

5 Executive Summary of Biliary Tract Cancer

6 Biliary Tract Cancer Epidemiology and Market Methodology

7 Biliary Tract Cancer Epidemiology and Patient Population

8 Biliary Tract Cancer Patient Journey

9 Biliary Tract Cancer Treatment Algorithm, Biliary Tract Cancer Current Treatment, and Medical Practices

10 Key Endpoints in Biliary Tract Cancer Clinical Trials

11 Biliary Tract Cancer Marketed Therapies

12 Biliary Tract Cancer Emerging Therapies

13 Biliary Tract Cancer: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Biliary Tract Cancer

16 Biliary Tract Cancer Market Key Opinion Leaders Reviews

18 Biliary Tract Cancer Market Drivers

19 Biliary Tract Cancer Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Biliary Tract Cancer Epidemiology 2034

DelveInsight’s “Biliary Tract Cancer – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Biliary Tract Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Biliary Tract Cancer Pipeline 2024

“Biliary Tract Cancer Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Biliary Tract Cancer market. A detailed picture of the Biliary Tract Cancer pipeline landscape is provided, which includes the disease overview and Biliary Tract Cancer treatment guidelines.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Biliary Tract Cancer Market Expected to rise, 2034 | Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme,

Age-Related Macular Degeneration Market Expected to rise, 2034 | Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Regeneron Pharmaceuticals, Novar

“Age-Related Macular Degeneration market growth”

The Age-Related Macular Degeneration market growth is driven by factors like increase in the prevalence of Age-Related Macular Degeneration, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Age-Related Macular Degeneration market report also offers comprehensive insights into the Age-Related Macular Degeneration market size, share, Age-Related Macular Degeneration epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Age-Related Macular Degeneration market size growth forward.

Some of the key highlights from the Age-Related Macular Degeneration Market Insights Report:

Several key pharmaceutical companies, including ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Biosciences, Daewoong Pharmaceutical, HK inno.N Corporation, Jeil Pharmaceutical, Onconic Therapeutics, Plexxikon, Renexxion, Taiho Pharmaceutical, Takeda, Trio Medicines, and others, are developing novel products to improve the Age-Related Macular Degeneration treatment outlook.
In January 2025, Astellas Pharma announced that the U.S. FDA had accepted the Class 1 resubmission of the supplemental New Drug Application (sNDA) for IZERVAY, a treatment targeting geographic atrophy related to age-related macular degeneration.
The market size for Age-related Macular Degeneration (AMD) in seven major markets is divided into two categories: Dry-AMD and Wet-AMD. In 2021, the total AMD market size was estimated at approximately USD 9,840 million and is projected to grow by 2034. Specifically, the market size for Dry-AMD was around USD 1,377 million, while Wet-AMD accounted for approximately USD 8,463 million, both of which are expected to expand further by 2034.
In 2021, the total number of prevalent Age-related Macular Degeneration (AMD) cases in the seven major markets (7MM) was approximately 51,743,361. This figure is projected to grow at a compound annual growth rate (CAGR) of 1.6% by 2034. In the United States, there were around 17,282,569 prevalent cases of AMD in 2021.
Among the EU5 countries, Germany had the highest number of AMD cases, with 7,850,793 cases in 2021, followed by France. Japan accounted for approximately 21% of AMD prevalent cases within the 7MM during the same year.
The total diagnosed AMD cases in 2021 across the 7MM were approximately 38,807,521, with the United States reporting the highest number of diagnosed cases.
Type-specific analysis revealed approximately 3,880,752 cases of Wet-AMD and 34,926,768 cases of Dry-AMD in the 7MM in 2021. These numbers are expected to increase significantly by 2034.
The anticipated launch of new therapies, along with an increasing number of diagnosed AMD cases, is likely to drive market growth in the coming years. Emerging treatments such as OPT-302, KSI-301, RGX-314, AKST4290, and others hold significant potential to positively impact the Wet-AMD market size.
As per DelveInsight analysis, the Age-Related Macular Degeneration market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Age-Related Macular Degeneration Market Landscape

Age-Related Macular Degeneration Overview

Age-related Macular Degeneration (AMD) is the leading cause of blindness among elderly individuals in developed countries. This eye condition progressively affects the central vision required for tasks such as driving, reading, recognizing faces, and perceiving colors. As AMD advances, it results in the loss of central vision, leaving many patients unable to perform activities involving color and detail, significantly reducing their quality of life. While the exact mechanisms underlying AMD are not fully understood, advancements in genetic technology have identified various polymorphisms uniquely associated with the disease.

AMD is marked by the gradual degeneration of the macula, the central portion of the retina, leading to central vision loss. Clinically, it is categorized into early, intermediate, or late stages, based on features such as drusen, pigmentation abnormalities, retinal pigment epithelium (RPE) atrophy, and exudative choroidal neovascularization (CNV).

Additionally, AMD can be classified into two forms: dry (atrophic or non-neovascular) and wet (exudative or neovascular).

Do you know the treatment paradigms for different countries? Download our Age-Related Macular Degeneration Market Sample Report

Age-Related Macular Degeneration Epidemiology Segmentation

DelveInsight’s Age-Related Macular Degeneration market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Age-Related Macular Degeneration historical patient pools and forecasted Age-Related Macular Degeneration patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Age-Related Macular Degeneration Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

Age-Related Macular Degeneration Prevalence
Age-Specific Age-Related Macular Degeneration Prevalence
Gender-Specific Age-Related Macular Degeneration Prevalence
Diagnosed and Treatable Cases of Age-Related Macular Degeneration

Visit for more @ Age-Related Macular Degeneration Epidemiological Insights

Age-Related Macular Degeneration Market OutlookAge-related Macular Degeneration (AMD) is a chronic, progressive disease of the central retina and the leading cause of irreversible blindness in the Western world and Asia-Pacific regions. Globally, approximately 8.7% of the population is affected by AMD. The wet form of the disease accounts for over 90% of severe central visual acuity (VA) loss associated with AMD.

Wet AMD Market Outlook:

The introduction of anti-VEGF intravitreal injections has revolutionized wet AMD treatment by effectively halting its pathophysiological progression, restoring retinal morphology, and preserving its function. Over the years, anti-VEGF injections have become the standard of care, outperforming earlier treatments like photodynamic therapy (PDT) and laser photocoagulation. Current therapies such as Lucentis (ranibizumab), Eylea (aflibercept), and Avastin (bevacizumab) effectively resolve exudative signs in most patients. Additionally, Faricimab and Susvimo have recently received approval for wet AMD management.

Dry AMD Market Outlook:

Currently, no approved therapies are available for dry AMD, leaving a significant unmet need for treatments to slow disease progression. The pathophysiology of dry AMD remains poorly understood, and the advanced stage of the disease may contribute to challenges in achieving primary outcomes rather than a lack of action on specific therapeutic targets. DelveInsight’s market analysis excludes other treatment options such as procedures and lifestyle management, focusing solely on pharmacological approaches for market size estimation in the 7MM.

Age-Related Macular Degeneration Marketed Drugs

Eylea (aflibercept): Regeneron Pharmaceuticals
Beovu (brolucizumab): Novartis
Lucentis (ranibizumab): Roche

Age-Related Macular Degeneration Emerging Drugs

OPT-302: Opthea Limited
KSI-301: Kodiak Sciences Inc.
RGX-314: Regenxbio
Danicopan (ALXN2040): Alexion Pharmaceuticals and AstraZeneca
EG-301: Evergreen Therapeutics

Age-Related Macular Degeneration Key Companies

Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics, and others

For more information, visit Age-Related Macular Degeneration Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Age-Related Macular Degeneration Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Age-Related Macular Degeneration, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Age-Related Macular Degeneration epidemiology in the 7MM
Age-Related Macular Degeneration marketed and emerging therapies
Age-Related Macular Degeneration companies
Age-Related Macular Degeneration market drivers and barriers

Table of Contents:

1 Age-Related Macular Degeneration Market Key Comprehensive Insights

2 Age-Related Macular Degeneration Market Report Introduction

3 Competitive Intelligence Analysis for Age-Related Macular Degeneration

4 Age-Related Macular Degeneration Market Analysis Overview at a Glance

5 Executive Summary of Age-Related Macular Degeneration

6 Age-Related Macular Degeneration Epidemiology and Market Methodology

7 Age-Related Macular Degeneration Epidemiology and Patient Population

8 Age-Related Macular Degeneration Patient Journey

9 Age-Related Macular Degeneration Treatment Algorithm, Age-Related Macular Degeneration Current Treatment, and Medical Practices

10 Key Endpoints in Age-Related Macular Degeneration Clinical Trials

11 Age-Related Macular Degeneration Marketed Therapies

12 Age-Related Macular Degeneration Emerging Therapies

13 Age-Related Macular Degeneration: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Age-Related Macular Degeneration

16 Age-Related Macular Degeneration Market Key Opinion Leaders Reviews

18 Age-Related Macular Degeneration Market Drivers

19 Age-Related Macular Degeneration Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Age-Related Macular Degeneration Epidemiology 2034

DelveInsight’s “Age-Related Macular Degeneration – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Age-Related Macular Degeneration epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Age-Related Macular Degeneration Pipeline 2024

“Age-Related Macular Degeneration Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Age-Related Macular Degeneration market. A detailed picture of the Age-Related Macular Degeneration pipeline landscape is provided, which includes the disease overview and Age-Related Macular Degeneration treatment guidelines.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Age-Related Macular Degeneration Market Expected to rise, 2034 | Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Regeneron Pharmaceuticals, Novar

Alliance Senior Care Provides Comprehensive Veteran Home Care in Bloomfield Hills, MI

Veterans and their families gain easier access to quality in-home care services in Bloomfield Hills, MI.

Bloomfield Hills, MI – Alliance Senior Care, a leading provider of home care services, reaffirms its dedication to supporting veterans and their families by offering comprehensive and easily accessible Veteran home care in Bloomfield Hills, MI. Recognizing veterans’ unique needs, Alliance Senior Care ensures that every family receives personalized care plans designed to enhance the quality of life for those served.

“At Alliance Senior Care, we are proud to support our veterans and their families with compassionate, reliable veteran in-home care in Bloomfield Hills, MI,” said Dina Hurnevich, Owner of Alliance Senior Care. “Our commitment is to ensure that the heroes of our community have access to the highest quality of care, empowering them to live comfortably and with dignity in their homes.”

The need for Veteran home care in Bloomfield Hills, MI, has grown significantly. Many families seek professional assistance to manage daily care and specialized medical needs. Alliance Senior Care’s veteran-focused home care services are tailored to address mobility challenges, chronic conditions, and overall wellness, ensuring veterans receive the support they need to thrive at home.

Veteran home care services are crucial in improving seniors’ mental and emotional well-being. By providing companionship and consistent support, caregivers help reduce feelings of isolation and loneliness, common among aging veterans. Familiarity with home surroundings and compassionate care can significantly boost morale and overall happiness for seniors, allowing them to maintain a positive outlook on life.

Additionally, these services ensure veterans receive the medical attention and assistance required to manage chronic illnesses. Skilled caregivers are trained to monitor health conditions, provide medication reminders, and coordinate with healthcare providers. This proactive approach helps prevent unnecessary hospital visits and promotes better long-term health outcomes, allowing seniors to enjoy a higher quality of life.

Home care for veterans also supports physical independence and mobility. Caregivers assist with daily activities such as bathing, dressing, and preparing meals, enabling seniors to continue living comfortably in their homes. By providing personalized support, Alliance Senior Care helps veterans maintain their dignity and independence, which are essential for their confidence and self-esteem.

These services benefit veterans and their families, offering peace of mind through skilled caregiving and personalized attention. Whether assisting with daily activities or managing complex care needs, Alliance Senior Care is dedicated to providing superior veteran in-home care in Bloomfield Hills, MI.

For more information on Alliance Senior Care and their Veteran home care in Bloomfield Hills, MI, please visit their website at https://alliancesrcare.com.

About Alliance Senior Care:

Alliance Senior Care is a trusted provider of personalized home care services in Bloomfield Hills, MI. The team at Alliance Senior Care focuses on quality, compassion, and professionalism and offers specialized care for veterans, seniors, and individuals with chronic conditions. Their mission is to enhance clients’ well-being through tailored care plans and exceptional support, ensuring comfort and dignity for every family they serve.

Media Contact
Company Name: Alliance Senior Care
Contact Person: Dina Hurnevich
Email: Send Email
Phone: +1 248 274 2170
Address:7 W SQUARE LAKE RD
City: Bloomfield Hills
State: MI 48302-0462
Country: United States
Website: alliancesrcare.com

Biliary Atresia Market Expected to rise, 2034 | Mirium Pharmaceuticals, Albireo, Intercept Pharmaceuticals, expected to drive market

“Biliary Atresia Market 2034”

The Biliary Atresia market growth is driven by factors like increase in the prevalence of Biliary Atresia, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Biliary Atresia market report also offers comprehensive insights into the Biliary Atresia market size, share, Biliary Atresia epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Biliary Atresia market size growth forward.

Some of the key highlights from the Biliary Atresia Market Insights Report:

Several key pharmaceutical companies, including Mirium Pharmaceuticals, Albireo, Intercept Pharmaceuticals, and others, are developing novel products to improve the Biliary Atresia treatment outlook.
DelveInsight estimates that in 2023, there were approximately 609 new cases of biliary atresia across the 7MM. The US accounted for nearly 56% of these cases, while EU4 and the UK represented 28%, and Japan accounted for 16%.
The biliary atresia market is poised for steady growth, with a strong compound annual growth rate (CAGR) expected from 2024 to 2034. Key factors driving this market expansion in the US include the increasing incidence of the disease, advancements in diagnostic methods, and growing acceptance of treatments. As a result, the biliary atresia drugs market is projected to experience significant growth, with a CAGR of 7.7%.
Despite these advancements, there is still a considerable treatment gap for biliary atresia due to the lack of approved drug therapies, with current treatments primarily relying on surgical procedures like the Kasai operation and liver transplantation. Given the substantial unmet needs in biliary atresia, several promising drugs are currently under development, targeting the condition, including odevixibat and obeticholic acid, among others.
As per DelveInsight analysis, the Biliary Atresia market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Biliary Atresia Market Landscape

Biliary Atresia Overview

Biliary atresia is a neonatal liver condition characterized by progressive obstruction and fibrosis of the extrahepatic biliary tree, along with fibrosis and inflammation of the liver tissue. The exact cause and mechanisms behind biliary atresia are still unclear. Recent research is exploring potential pathogenic factors, such as genetic predisposition, immune system involvement, and environmental factors like viruses and toxins. It is likely that there isn’t a single cause but rather a range of harmful factors that could lead to a common outcome of extrahepatic bile duct obstruction and liver fibrosis.

The symptoms of biliary atresia typically emerge between 2 to 6 weeks of age. These include jaundice, which causes a yellowish tint to the skin and the whites of the eyes, pale stools, and dark urine. Infants may also experience abdominal swelling and/or an enlarged liver (hepatomegaly).

Do you know the treatment paradigms for different countries? Download our Biliary Atresia Market Sample Report

Biliary Atresia Epidemiology Insights

DelveInsight’s epidemiology model estimates that in 2023, there were approximately 338 new cases of biliary atresia in the US, with this number expected to rise by 2034.
In 2023, there were about 17 cases of Type I, 7 cases of Type II, and 315 cases of Type III. Our projections indicate that these case numbers will change over the forecast period from 2024 to 2034.

Biliary Atresia Epidemiology Segmentation

DelveInsight’s Biliary Atresia market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Biliary Atresia historical patient pools and forecasted Biliary Atresia patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Biliary Atresia Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

Biliary Atresia Prevalence
Age-Specific Biliary Atresia Prevalence
Gender-Specific Biliary Atresia Prevalence
Diagnosed and Treatable Cases of Biliary Atresia

Visit for more @ Biliary Atresia Epidemiological Insights

Biliary Atresia Market Outlook

Biliary atresia is characterized by the fibro-proliferative obliteration of the biliary tree, which progressively leads to hepatic fibrosis, cirrhosis, and eventually end-stage liver failure. The treatment for biliary atresia is primarily surgical and generally involves two stages. In the first few months of life, a Hepatoportoenterostomy (commonly known as the “Kasai” procedure, with possible modifications) is performed to restore biliary flow to the intestine and minimize further liver damage. If this procedure fails or if the disease advances to biliary cirrhosis and life-threatening complications, a liver transplant is required, making biliary atresia the most common pediatric indication for liver transplantation.

In terms of postoperative care, management following Hepatoportoenterostomy includes interventions such as the use of choleretics and anti-inflammatory medications, nutritional rehabilitation, supplementation with fat-soluble vitamins, prevention of cholangitis, and management of portal hypertension and its related complications. Administration of choleretics like ursodeoxycholic acid (UDCA) is a standard practice in biliary atresia, although its clinical effectiveness has not been definitively proven. Taken orally, UDCA is a hydrophilic bile acid that alters the balance of bile acids toward hydrophilic forms. This is believed to stabilize cell membranes and reduce the generation of free radicals, thereby protecting mitochondria from damage.

High-energy supplements, such as glucose polymers or medium-chain triglyceride (MCT) oil, are added to formula or solid foods to support nutritional needs. MCT oil or MCT-based formulas are particularly useful because they are calorie-dense and can be easily absorbed by patients with cholestasis, as they do not require micellar solubilization. The treatment of biliary atresia is comprehensive, focusing on both addressing the underlying cause and managing symptoms to enhance patient comfort.

Biliary Atresia Emerging Drugs

BYLVAY (odevixibat): Ipsen
Obeticholic Acid: Intercept Pharmaceuticals

Biliary Atresia Key Companies

Mirium Pharmaceuticals
Albireo
Intercept Pharmaceuticals, and others

For more information, visit Biliary Atresia Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Biliary Atresia Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Biliary Atresia, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Biliary Atresia epidemiology in the 7MM
Biliary Atresia marketed and emerging therapies
Biliary Atresia companies
Biliary Atresia market drivers and barriers

Table of Contents:

1 Biliary Atresia Market Key Comprehensive Insights

2 Biliary Atresia Market Report Introduction

3 Competitive Intelligence Analysis for Biliary Atresia

4 Biliary Atresia Market Analysis Overview at a Glance

5 Executive Summary of Biliary Atresia

6 Biliary Atresia Epidemiology and Market Methodology

7 Biliary Atresia Epidemiology and Patient Population

8 Biliary Atresia Patient Journey

9 Biliary Atresia Treatment Algorithm, Biliary Atresia Current Treatment, and Medical Practices

10 Key Endpoints in Biliary Atresia Clinical Trials

11 Biliary Atresia Marketed Therapies

12 Biliary Atresia Emerging Therapies

13 Biliary Atresia: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Biliary Atresia

16 Biliary Atresia Market Key Opinion Leaders Reviews

18 Biliary Atresia Market Drivers

19 Biliary Atresia Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Biliary Atresia Epidemiology 2034

DelveInsight’s “Biliary Atresia – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Biliary Atresia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Biliary Atresia Pipeline 2024

“Biliary Atresia Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Biliary Atresia market. A detailed picture of the Biliary Atresia pipeline landscape is provided, which includes the disease overview and Biliary Atresia treatment guidelines.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Biliary Atresia Market Expected to rise, 2034 | Mirium Pharmaceuticals, Albireo, Intercept Pharmaceuticals, expected to drive market